Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, and Chronic Myeloid Leukemia Treatments.
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide
Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity
Grade I acute graft-vs-host disease: Treat or not?
Risk prediction for clonal cytopenia: multicenter real-world evidence
HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
A Day 14 Endpoint for Acute GVHD Clinical Trials
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis